ClinicalTrials.gg
CompletedNCT00396201Updated Mar 13, 2014Results posted

AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease

A Phase 2 interventional study of G-CSF Plus Plerixafor in Hodgkin's Disease, sponsored by Genzyme, a Sanofi Company. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-03-13.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing Granulocyte Colony-Stimulating Factor in Hodgkin Disease — 1 open to participants now, 1 under way, none of them phase 3. Granulocyte Colony-Stimulating Factor · Hodgkin Disease.

Enrollment
8th of 12
22 · median 28
Started
2004
with 1 other
Phase 2
10 of 12
1 open now
Registered
4th of 12
by date
Lead sponsor
2 of 12
Genzyme, a Sanofi Company

Among the 12 studies testing Granulocyte Colony-Stimulating Factor in Hodgkin Disease, this one is the 8th largest by enrollment, is one of 2 that started in 2004, is one of 10 in phase 2, and was the 4th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

1 of the 12 studies testing Granulocyte Colony-Stimulating Factor in Hodgkin Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About Granulocyte Colony-Stimulating Factor

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing Granulocyte Colony-Stimulating Factor in Hodgkin Disease, or all of them as a file.
02

Study summary

Participants with Hodgkin's Disease (HD) who have been treated with cyto-reductive chemotherapy, who are to undergo autologous stem cell transplantation, and who meet the inclusion/exclusion criteria are eligible to enter this efficacy, safety and pharmacokinetic (PK) study. The only changes to the standard of care is the addition of plerixafor to a granulocyte-colony stimulating factor (G-CSF) mobilization regimen on each day prior to apheresis. The purpose of this protocol is to determine the proportion of participants who reach a target number of CD34+ stem cells (≥5*10\^6 cells/kg) after hematopoietic stem cell mobilization with G-CSF and plerixafor. Safety and PK parameters are also collected.

Read the detailed description

Participants with HD who have been treated with cyto-reductive chemotherapy, who are to undergo autologous stem cell transplantation, and who meet the inclusion/exclusion criteria are eligible to enter this study. The only changes to the standard of care is the addition of plerixafor to a G-CSF mobilization regimen on the day prior to apheresis and the collection of blood samples for pharmacokinetic (PK) analysis and pharmacodynamics (PD) analysis by CD34+ fluorescence-activated cell sorting (FACS) analysis. Blood samples for PK and CD34+ FACS analyses will be obtained prior to and after the first dose of plerixafor. Participants will undergo mobilization with G-CSF (10 µg/kg daily) and will receive plerixafor (240 µg/kg) on each day prior to apheresis. Participants will be apheresed for up to 5 consecutive days in order to collect the target number of CD34+ stem cells, (≥5*10\^6 cells/kg). After apheresis, all participants will be treated with high dose chemotherapy in preparation for transplantation. Participants will be transplanted with cells obtained from the G-CSF plus plerixafor mobilization regimen. In the event that a sufficient number of cells for transplantation are not obtained from the collection, cells may be retained and pooled for transplantation at the investigator's discretion.

The primary endpoint is the proportion of HD participants who collect ≥5*10\^6 CD34+ cells/kg with this mobilization regimen. The secondary endpoints include the safety of this mobilization regimen, the proportion of participants who collect ≥2*10\^6 CD34+ cells/kg, the change in CD34+ cells circulating in the peripheral blood after a dose of plerixafor, and the number of days of apheresis required to obtain ≥5*10\^6 CD34+ cells/kg. In addition, success of the transplantation will be evaluated by measuring the time to engraftment of PMNs and PLTs. Participants will be followed for 12 months to assess transplant durability.

This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.

03

Conditions studied

  • Hodgkin's Disease

Browse trials for

Keywords

  • Hodgkin's Disease
  • Stem cell mobilization
  • apheresis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of HD eligible for transplantation
  • No more than 3 prior regimens of chemotherapy (Rituximab is not considered chemotherapy for the purpose of this study.)
  • 4 weeks since last cycle of chemotherapy
  • (ECOG) performance status of 0 or 1
  • The patient has recovered from all acute toxic effects of prior chemotherapy
  • White blood cell count (WBC) >3.0*10\^9/L
  • Absolute polymorphonuclear cells (PMN) count >1.5*10\^9/L
  • (PLT) count >100*10\^9/L
  • Serum creatinine ≤2.2 mg/DL
  • Serum glutamic oxaloacetic transaminase (), serum glutamic pyruvic transaminase (SGPT) and total \<2 x (ULN)
  • Left ventricle >45% by normal echocardiogram or multiple-gated acquisition (MUGA) scan
  • Forced expiratory volume of the lung in the first second () >60% of predicted or diffusing capacity of the lung for carbon monoxide (DLCO) >45% of predicted
  • Negative for (HIV)

Exclusion criteria

Exclusion Criteria:

  • A co-morbid condition which, in the view of the investigator, renders the patient at high risk for treatment complications
  • Patients who have failed previous collections
  • A residual acute medical condition resulting from prior chemotherapy
  • Hodgkin's disease involving the central nervous system
  • Acute infection
  • Fever (temp >38°C/100.4°F)
  • Patients whose actual body weight exceeds 150% of their ideal body weight
  • History of ventricular arrhythmias
  • History of paresthesias
  • Patients who previously received experimental therapy within 4 weeks of enrolling in this study or who are currently enrolled in another experimental study during the mobilization period
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Participants with Hodgkin's Disease (HD)

    Participants with Hodgkin's Disease who were eligible for autologous peripheral blood stem cell transplantation.

    Drug: G-CSF Plus Plerixafor

Interventions

  • DrugG-CSF Plus Plerixafor

    Drug pages: Granulocyte Colony-Stimulating Factor · Plerixafor

    Randomized participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.

    Also known as: Mozobil, AMD3100

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF

    The proportion of total participants who mobilized ≥5\*10\^6 CD34+ cells/kg based on data from local laboratories.

    Time frame: Day 5 up to Day 9

Secondary outcomes

  1. Overall Participant Counts of Adverse Events During the Treatment Period

    Adverse Events were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for severity (mild, moderate, severe and life-threatening) and relatedness (5 steps from 'not related' to 'definitely related') to study treatment. Time frame starts on the first day of G-CSF mobilization to the day prior to chemotherapy/ablative treatment in preparation for transplant. See the separate Serious Adverse Event section for a summary of AEs the investigator assessed as serious.

    Time frame: Day 0 - approximately day 38

  2. Proportion of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF

    The proportion of total participants who mobilized ≥2\*10\^6 CD34+ cells/kg based on data from local laboratories.

    Time frame: Day 5 up to day 9

  3. Fold (Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL

    The fold increase was measured by fluorescence activated cell sorting (FACS) analysis using local laboratory data and was expressed as a ratio. Fold increase = (pre-apheresis PB CD34+ cells/µL)/(pre-plerixafor dosing PB CD34+ cells/µL).

    Time frame: Days 4-5 (first dose of plerixafor to apheresis)

  4. Participant Counts Grouped by Number of Apheresis Days Required to Collect ≥ 5*10^6 CD34+ Cells/kg

    Counts of participants grouped by the number of apheresis days needed to collect a target for transplantation of ≥5\*10\^6 CD34+ cells/kg as determined by local laboratory data.

    Time frame: Day 5 up to day 9

  5. Number of Days Post-Transplantation to Polymorphonuclear Leukocyte (PMN) Engraftment

    Median number of days to PMN engraftment following transplantation. Engraftment was defined as PMN counts ≥ 0.5\*10\^9/L for 3 consecutive days or ≥ 1.0\*10\^9/L for 1 day. Time to engraftment corresponded to the first day that the criteria were met.

    Time frame: Up to Month 13 (up to 12 months post transplant)

  6. Number of Days Post Transplantation to Platelet (PLT) Engraftment

    Median number of days to PLT engraftment following transplantation. Engraftment success was evaluated according to local site practice. Time to engraftment corresponded to the first day that criteria were met.

    Time frame: Up to Month 13 (up to 12 months post transplant)

  7. Number of Participants With a Durable Graft at 12 Months

    Graft durability was assessed by the Investigator based on complete blood count (CBC) and differential analyses at 12 months post transplantation. A graft was considered durable if blood counts were normal (acceptable) and still met the criteria for PLT and PMN engraftment.

    Time frame: 13 months

  8. Maximum Plasma Concentration (Cmax) Following a Single Dose of Plerixafor

    Maximum plasma concentration (Cmax) of plerixafor following the first single dose of 240 ug/kg plerixafor administered.

    Time frame: Day 4

  9. Time to Maximum Plasma Concentration (Tmax) Following a Single Dose of Plerixafor

    Time to maximum plasma concentration (Tmax) of plerixafor following the first single dose of 240 ug/kg plerixafor was determined from direct observation of the data.

    Time frame: Day 4

  10. Half-life (T1/2) Following a Single Dose of Plerixafor

    Plasma elimination half-life (T1/2) following a single dose of 240 ug/kg plerixafor.

    Time frame: Day 4

  11. Area Under the Plasma Concentration-time Curve From 0 to 10 Hours (AUC0-10) Following a Single Dose of Plerixafor

    Area under the plasma concentration-time curve from 0 to 10 hours (AUC0-10) following the first single dose of 240 ug/kg plerixafor.

    Time frame: Days 4-5

  12. Apparent Clearance (CL/F) of Single-dose Plerixafor

    Apparent clearance was calculated the mean dose of plerixafor divided by the area under the plasma concentration-time curve from 0 hours to infinity (AUC0-inf).

    Time frame: Day 4-5

  13. Apparent Volume of Distribution (Vz/F) Following a Single-dose of Plerixafor

    The volume of distribution (Vz/F) was calculated as apparent clearance divided by the terminal elimination rate constant.

    Time frame: Day 4

07

Results

Posted Oct 6, 2010

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestoneParticipants With Hodgkin's Disease (HD)
Started22
Completed22
Not completed0
Follow-up Period
Participant flow — Follow-up Period
MilestoneParticipants With Hodgkin's Disease (HD)
Started21
Completed21
Not completed0

Outcome measures

PrimaryProportion of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF

The proportion of total participants who mobilized ≥5\*10\^6 CD34+ cells/kg based on data from local laboratories.

Time frame:
Day 5 up to Day 9
Reported as:
Number · proportion of participants
Proportion of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF
proportion of participantsParticipants With Hodgkin's Disease (HD)
Proportion achieving ≥5*10^6 CD34+ cells/kg0.68
Proportion not achieving ≥5*10^6 CD34+ cells/kg0.32
SecondaryOverall Participant Counts of Adverse Events During the Treatment Period

Adverse Events were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for severity (mild, moderate, severe and life-threatening) and relatedness (5 steps from 'not related' to 'definitely related') to study treatment. Time frame starts on the first day of G-CSF mobilization to the day prior to chemotherapy/ablative treatment in preparation for transplant. See the separate Serious Adverse Event section for a summary of AEs the investigator assessed as serious.

Time frame:
Day 0 - approximately day 38
Reported as:
Number · participants
Overall Participant Counts of Adverse Events During the Treatment Period
participantsParticipants With Hodgkin's Disease (HD)
Reporting at least one AE17
Severity - Mild5
Severity - Moderate11
Severity - Severe1
Severity - Life Threatening0
Relationship - Not Related2
Relationship - Probably Not Related1
Relationship - Possibly Related12
Relationship - Probably Related1
Relationship - Definitely Related1
SecondaryProportion of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF

The proportion of total participants who mobilized ≥2\*10\^6 CD34+ cells/kg based on data from local laboratories.

Time frame:
Day 5 up to day 9
Reported as:
Number · proportion of participants
Proportion of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF
proportion of participantsParticipants With Hodgkin's Disease (HD)
Proportion achieving ≥2*10^6 CD34+ cells/kg0.95
Proportion not achieving ≥2*10^6 CD34+ cells/kg0.05
SecondaryFold (Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL

The fold increase was measured by fluorescence activated cell sorting (FACS) analysis using local laboratory data and was expressed as a ratio. Fold increase = (pre-apheresis PB CD34+ cells/µL)/(pre-plerixafor dosing PB CD34+ cells/µL).

Time frame:
Days 4-5 (first dose of plerixafor to apheresis)
Reported as:
Mean · ratio
Fold (Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL
ratioParticipants With Hodgkin's Disease (HD)
Fold (Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL3.2 ± 1.1
SecondaryParticipant Counts Grouped by Number of Apheresis Days Required to Collect ≥ 5*10^6 CD34+ Cells/kg

Counts of participants grouped by the number of apheresis days needed to collect a target for transplantation of ≥5\*10\^6 CD34+ cells/kg as determined by local laboratory data.

Time frame:
Day 5 up to day 9
Reported as:
Number · participants
Participant Counts Grouped by Number of Apheresis Days Required to Collect ≥ 5*10^6 CD34+ Cells/kg
participantsParticipants With Hodgkin's Disease (HD)
1 day of apheresis7 ± 0.9
2 days of apheresis6
3 days of apheresis2
SecondaryNumber of Days Post-Transplantation to Polymorphonuclear Leukocyte (PMN) Engraftment

Median number of days to PMN engraftment following transplantation. Engraftment was defined as PMN counts ≥ 0.5\*10\^9/L for 3 consecutive days or ≥ 1.0\*10\^9/L for 1 day. Time to engraftment corresponded to the first day that the criteria were met.

Time frame:
Up to Month 13 (up to 12 months post transplant)
Reported as:
Median · days
Number of Days Post-Transplantation to Polymorphonuclear Leukocyte (PMN) Engraftment
daysParticipants With Hodgkin's Disease (HD)
Number of Days Post-Transplantation to Polymorphonuclear Leukocyte (PMN) Engraftment9.0 ± 1.2
SecondaryNumber of Days Post Transplantation to Platelet (PLT) Engraftment

Median number of days to PLT engraftment following transplantation. Engraftment success was evaluated according to local site practice. Time to engraftment corresponded to the first day that criteria were met.

Time frame:
Up to Month 13 (up to 12 months post transplant)
Reported as:
Median · days
Number of Days Post Transplantation to Platelet (PLT) Engraftment
daysParticipants With Hodgkin's Disease (HD)
Number of Days Post Transplantation to Platelet (PLT) Engraftment19.0 ± 3.8
SecondaryNumber of Participants With a Durable Graft at 12 Months

Graft durability was assessed by the Investigator based on complete blood count (CBC) and differential analyses at 12 months post transplantation. A graft was considered durable if blood counts were normal (acceptable) and still met the criteria for PLT and PMN engraftment.

Time frame:
13 months
Reported as:
Number · participants
Number of Participants With a Durable Graft at 12 Months
participantsParticipants With Hodgkin's Disease (HD)
Number of Participants With a Durable Graft at 12 Months21
SecondaryMaximum Plasma Concentration (Cmax) Following a Single Dose of Plerixafor

Maximum plasma concentration (Cmax) of plerixafor following the first single dose of 240 ug/kg plerixafor administered.

Time frame:
Day 4
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) Following a Single Dose of Plerixafor
ng/mLParticipants With Hodgkin's Disease (HD)
Maximum Plasma Concentration (Cmax) Following a Single Dose of Plerixafor831 ± 183
SecondaryTime to Maximum Plasma Concentration (Tmax) Following a Single Dose of Plerixafor

Time to maximum plasma concentration (Tmax) of plerixafor following the first single dose of 240 ug/kg plerixafor was determined from direct observation of the data.

Time frame:
Day 4
Reported as:
Mean · hours
Time to Maximum Plasma Concentration (Tmax) Following a Single Dose of Plerixafor
hoursParticipants With Hodgkin's Disease (HD)
Time to Maximum Plasma Concentration (Tmax) Following a Single Dose of Plerixafor0.6 ± 0.4
SecondaryHalf-life (T1/2) Following a Single Dose of Plerixafor

Plasma elimination half-life (T1/2) following a single dose of 240 ug/kg plerixafor.

Time frame:
Day 4
Reported as:
Mean · hours
Half-life (T1/2) Following a Single Dose of Plerixafor
hoursParticipants With Hodgkin's Disease (HD)
Half-life (T1/2) Following a Single Dose of Plerixafor3.5 ± 0.7
SecondaryArea Under the Plasma Concentration-time Curve From 0 to 10 Hours (AUC0-10) Following a Single Dose of Plerixafor

Area under the plasma concentration-time curve from 0 to 10 hours (AUC0-10) following the first single dose of 240 ug/kg plerixafor.

Time frame:
Days 4-5
Reported as:
Mean · ng*hr/mL
Area Under the Plasma Concentration-time Curve From 0 to 10 Hours (AUC0-10) Following a Single Dose of Plerixafor
ng*hr/mLParticipants With Hodgkin's Disease (HD)
Area Under the Plasma Concentration-time Curve From 0 to 10 Hours (AUC0-10) Following a Single Dose of Plerixafor3572 ± 772
SecondaryApparent Clearance (CL/F) of Single-dose Plerixafor

Apparent clearance was calculated the mean dose of plerixafor divided by the area under the plasma concentration-time curve from 0 hours to infinity (AUC0-inf).

Time frame:
Day 4-5
Reported as:
Mean · mL/hr
Apparent Clearance (CL/F) of Single-dose Plerixafor
mL/hrParticipants With Hodgkin's Disease (HD)
Apparent Clearance (CL/F) of Single-dose Plerixafor5138 ± 2029
SecondaryApparent Volume of Distribution (Vz/F) Following a Single-dose of Plerixafor

The volume of distribution (Vz/F) was calculated as apparent clearance divided by the terminal elimination rate constant.

Time frame:
Day 4
Reported as:
Mean · mL
Apparent Volume of Distribution (Vz/F) Following a Single-dose of Plerixafor
mLParticipants With Hodgkin's Disease (HD)
Apparent Volume of Distribution (Vz/F) Following a Single-dose of Plerixafor25464 ± 9002

Adverse events

Collected over Day 1 (start of G-CSF Mobilization plus Treatment/Apheresis) to the day before starting chemotherapy. Chemotherapy typically started within 30 days of the last apheresis (which may have occurred on Day 5, 6, 7, or 8).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants With Hodgkin's Disease (HD)—0/22 (0%)17/22 (77.3%)
Most frequent other events
Showing 10 of 43
Most frequent other events
EventParticipants With Hodgkin's Disease (HD)
Injection site erythemaGeneral disorders15/22
Back painMusculoskeletal and connective tissue disorders7/22
NauseaGastrointestinal disorders6/22
Bone painMusculoskeletal and connective tissue disorders6/22
FatigueGeneral disorders5/22
ParaesthesiaNervous system disorders5/22
Paraesthesia oralGastrointestinal disorders4/22
DiarrhoeaGastrointestinal disorders3/22
Injection site haemorrhageGeneral disorders3/22
ArthralgiaMusculoskeletal and connective tissue disorders3/22

Baseline characteristics

Age, Continuous
Age, Continuous(years)Participants With Hodgkin's Disease (HD)
Mean34.0 ± 12.5
Sex: Female, Male
Sex: Female, Male(Participants)Participants With Hodgkin's Disease (HD)
Female13
Male9
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Participants With Hodgkin's Disease (HD)
Caucasian22
08

Study locations

1 site
  • Washington University School of Medicine,Division of Bone Marrow Transplantation & Leukemia
    St Louis, Missouri 63110-1093, United States
09

References and documents

Publications

  • Cashen A, Lopez S, Gao F, Calandra G, MacFarland R, Badel K, DiPersio J. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008 Nov;14(11):1253-61. doi: 10.1016/j.bbmt.2008.08.011. PubMed 18940680 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2004, a primary completion of Oct 2006 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2010, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2006
First posted
Nov 6, 2006
Start
Nov 2004
Primary completionActual
Oct 2006
CompletionActual
Jan 2008
Results first posted
Oct 6, 2010
Last update
Mar 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00396201
First posted
Nov 6, 2006
Start date
Nov 2004
Primary completion
Oct 2006
Completion
Jan 2008
Results posted
Oct 6, 2010
Last update
Mar 13, 2014

Study contacts

Medical Monitor
study director · Genzyme, a Sanofi Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Granulocyte Colony-Stimulating Factor · Plerixafor

Start the discussion